Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | UNG | P13051 | 2/20 | 0.41 |
| ▸ | YTHDF3 | Q7Z739 | 1/20 | 0.40 |
| ▸ | YTHDF1 | Q9BYJ9 | 1/20 | 0.40 |
| ▸ | YTHDF2 | Q9Y5A9 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CCNO | P22674 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | APAF1 | O14727 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL3285066 | 0.98 | ALDH1A1 (0.45) | ALDH1A1LMNACA1TAAR1UNG | |
| SCHEMBL6073235 | 0.68 | MAPT (0.32) | CYP2A6ERN1 | |
| SCHEMBL3403046 | 0.67 | — | — | |
| SCHEMBL22851529 | 0.65 | GPR84 (0.47) | ALDH1A1LMNACA1UNGYTHDF3 | |
| SCHEMBL1787535 | 0.64 | CYP2A6 (0.47) | ALDH1A1LMNACA1CYP2A6CYP1A2 | |
| Orotic Acid SCHEMBL29394966 | 0.63 | ALDH1A1 (1.00) | ALDH1A1LMNACA1CYP1A2GPR84 | |
| Orotic Acid SCHEMBL20865 | 0.63 | ALDH1A1 (1.00) | ALDH1A1LMNACA1CYP1A2GPR84 | |
| SCHEMBL13918178 | 0.63 | — | — | |
| SCHEMBL3362001 | 0.63 | — | — | |
| SCHEMBL325682 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2014-10-16 | — | — | US | claimed |
| CN-104105691-A | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC | 2014-10-15 | — | — | CN | claimed |
| EP-2776407-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2014-09-17 | — | — | EP | claimed |
| WO-2013070657-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | WO | claimed |
| US-11739072-B2 | Heteroaryl compounds and their use | MINORYX THERAPEUTICS S.L. (ES) | 2023-08-29 | — | — | US | disclosed |
| US-11739072-B2 | Heteroaryl compounds and their use | MINORYX THERAPEUTICS S.L. (ES) | 2023-08-29 | — | — | US | disclosed |
| US-11739072-B2 | Heteroaryl compounds and their use | MINORYX THERAPEUTICS S.L. (ES) | 2023-08-29 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220135535-A1 | HETEROARYL COMPOUNDS AND THEIR USE | MINORYX THERAPEUTICS S.L. (ES) | 2022-05-05 | — | — | US | disclosed |
| US-20220135535-A1 | HETEROARYL COMPOUNDS AND THEIR USE | MINORYX THERAPEUTICS S.L. (ES) | 2022-05-05 | — | — | US | disclosed |
| EP-3759082-B1 | PROCESS FOR THE SYNTHESIS OF 6-CHLOROMETHYLURACIL | PROCOS SPA (IT) | 2022-04-20 | — | — | EP | disclosed |
| EP-3562811-B1 | HETEROARYL COMPOUNDS AND THEIR USE | MINORYX THERAPEUTICS S L (ES) | 2022-03-16 | — | — | EP | disclosed |
| WO-2001051479-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2001-07-19 | — | — | WO | disclosed |
| US-5348957-A | Gastrointestinal ulcer treatment | WARNER-LAMBERT COMPANY (US) | 1994-09-20 | — | — | US | disclosed |
| US-5270319-A | 5-hydroxy-2-pyrimidinylmethylene derivatives useful as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1993-12-14 | — | — | US | disclosed |
| WO-1993005039-A1 | 5-HYDROXY-2-PYRIMIDINYLMETHYLENE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-03-18 | — | — | WO | disclosed |
| US-5098888-A | Cholinergic agents and antispasmodic agents | ADIR ET COMPAGNIE (FR) | 1992-03-24 | — | — | US | disclosed |
| EP-0434576-A1 | Thermotropic adducts from non-mesogenic species bound by hydrogen bonds and method for their preparation | RHONE-POULENC CHIMIE (FR) | 1991-06-26 | — | — | EP | disclosed |
| US-4035395-A | Process for the preparation of ketones | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-12 | — | — | US | disclosed |
| US-4014889-A | Process for preparing ketones | BAYER AKTIENGESELLSCHAFT (DT) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135535-A1 | HETEROARYL COMPOUNDS AND THEIR USE | GBA1, GBA2, GAA | ALDH1A1 1097/4885LMNA 127/4885CA1 4618/4885 |
| US-11739072-B2 | Heteroaryl compounds and their use | GBA1, GBA2, GAA | ALDH1A1 1097/4885LMNA 127/4885CA1 4618/4885 |
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | MRGPRX1, MRGPRX2, AGTR1 | ALDH1A1 2797/4885LMNA 4628/4885CA1 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.